Main Article Content
The objective of this study is to test the efficacy and safety of Plai gel containing 1% Plai oil in treatment of mild to moderate acne vulgaris. Randomized, double blinded, placebo controlled trial was conducted in 60 healthy volunteers. The primary outcome is expressed in percentage reduction in total acne lesions (inflammatory lesions and non inflammatory lesions). Assessments were performed at week 2, 4, and 8. A percentage reduction in total acne lesions in plai group was higher than the placebo group at week 2 [6 times (95%CI: -16 to 28)] and week 4 [12 times (95%CI: -12 to 35)]. A percentage reduction in noninflammatory acne lesions in plai group was higher than the placebo group at week 2 [14 times (95%CI: -17 to 43)] and week 4 [26 times (95%CI: -4 to 64)]. However, such differences did not show statistical significance. At week 8, there were no differences between two groups. The plai group showed a significant reduction of noninflammatory acne lesions from the baseline at week 2 (45 ± 29 lesions) and week 4 (41 ± 25 lesions), while the placebo did not so. A percentage reduction in inflammatory acne lesions in plai group was lower than the placebo group at week 2 [2.9 (95%CI:-37.6 to 31.8)] and week 4 [12.1 (95%CI:-42.2 to 17.9), however, there were no significant differences. For the secondary outcome, success rate at week 8 was 39% in plai group and 31% in placebo group. However, this difference did not show statistical significance. Plai gel was safe. Adverse events were not found in this study. The compliance to use plai gel was greater than 90%. In conclusion, plai gel is promising to be used in treatment of mild to moderate acne, which the effect could be seen within the first month as compared to placebo.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
Berger R, Rizer R, Barba A, et al. 2007. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: A 12-week, multicenter, randomized, double-blind, parallel-group, Phase IV Trial. Clin Therapeut 29 (6): 1086-1097.
Bershad S, Kranjac SG, Parente JE, et al. 2002. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 138: 481-489.
Capizzi R, Landi F, Milani M, et al. 2004. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne: a randomized, investigator-masked, controlled trial. Br J Dermatol 151: 481-484.
Carson CE, Hammer KA, Riley TB. 2006. Melaleuca alternifolia (Tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 19: 50-62.
Charakida A, Charakida M, Chu AC.2007. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol 157: 569-574.
Choi JM, Lew VK, Kimball AB. 2006. A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatr Dermatol 23 (5): 421-427.
Enshaieh S, Jooya A, Siadat AH, et al. 2007. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol 73 (1): 22-25.
Giwanon R, Thubthimthed S, Rerk-am U, et al. 2000. Antimicrobial activity of terpinene-4-ol and sabinene. Thai J Pharm Sci 24: 27.
Gollnick H, Cunliffe W, Berson D, et al. 2003.Management of acne: A report from a global alliance to improve outcomes inacne. J Am Acad Dermatol 49(1) (suppl): S1-S37.
Haider A, Shaw JC. 2004. Treatment of acne vulgaris. JAMA 292: 726-735.
Homer LE, Leach DN, Lea D, et al. 2000. Natural variation in the essential oil content of Melaleuca alternifolia Cheel (Myrtaceae). Biochem Syst Ecol 28: 367-382.
Koo J. 2003. How do you foster medication adherence for better acne vulgarismanagement? Skinmed 2: 229-233.
Lertsatitthanakorn P, Taweechaisupapong S, Aromdee C, et al. 2006. In vitro bioactivities of essential oils used for acne control. IJA 16(1): 43-49.
Leyden JJ. 2003. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 49(3) (suppl): S200-S210. Liao DC. 2003. Management of acne. J Fam Pract52 (1): 43-51.
Pawin H, Beylot C, Chivot M, et al. 2004. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 14: 4-12.
Pithayanukul P, Tubprasert J, Wuthi-Udomlert M. 2007. In vitro antimicrobial activity of Zingiber cassumunar (Plai) oil and 5% plai oil gel. Phytother Res 21:164-169.
Swanson IK. 2003. Antibiotic resistance of Propionibacteirum acnes in acne vulgaris. Dermatol Nurs 5: 359-361.Thiboutot D. 2000. New treatments and therapeutic strategies for acne. Arch Fam Med 9: 179-187.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry “Acne Vulgaris: developing drug for treatment.” 2005 [Online]. http://www.fda.gov/cder/guidance/6499dft.pdf. Accessed June 28, 2007.
Wasuwat S, Wanisorn P, Mahintorntep B, et al. 1989. Studies on antimicrobial and antifungal activities of terpinen-4-ol extracted from Zingiber cassumunar Roxb. Thailand Institute of Scientific and Technological Research. Research Project No. 30-32/Rep.No.1.